Protagonist Therapeutics: Proprietary peptide technology platform to develop oral targeted therapy-based drugs that work by blocking biological pathways currently targeted by marketed injectable antibody drugs, and injectables for rare diseases. PTG-300, injectable hepcidin mimetic in Ph 2 Beta-Thalassemia study with initial results expected 2H19. PTG-200, partnered w Janssen, oral GI-restricted IL-23R antagonist for Crohn’s disease completed Ph 1 in November 2018. PN-943, oral GI-restricted alpha4beta7 integrin-specific antagonist in UC in Ph 1, with topline results expected 1H19.
Website:
Address:
521 Cottonwood Drive
Suite 100
Milpitas, CA 95035
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.